Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06648824 · ClinicalTrials.gov registry record · Phase 1
Study of How Mitapivat Affects Midazolam Blood Levels in Healthy Participants
A Phase 1 study, sponsored by Agios Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT06648824 is a Phase 1 study that has completed, run by Agios Pharmaceuticals. The registered enrollment target is 20 participants.
The verdict
NCT06648824, a Phase 1 study, has completed, sponsored by Agios Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
The primary purpose of this study is to assess the effect of mitapivat on the single oral dose pharmacokinetics (PK) of midazolam in healthy participants.
Interventions
- DRUG Midazolam
- DRUG Mitapivat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2024-10-17 |
| Est. Completion | 2024-12-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06648824
The ClinicalTrials.gov registry entry for NCT06648824 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Agios Pharmaceuticals, which has 44 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Midazolam is the first listed.
NCT06648824 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06648824 about?
NCT06648824 is a clinical study titled "Study of How Mitapivat Affects Midazolam Blood Levels in Healthy Participants". The primary purpose of this study is to assess the effect of mitapivat on the single oral dose pharmacokinetics (PK) of midazolam in healthy participants.
What is the current status of trial NCT06648824?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2024-10-17. Estimated completion is 2024-12-03.
What interventions are being tested in trial NCT06648824?
The interventions under investigation include: Midazolam (DRUG), Mitapivat (DRUG).
Who is sponsoring clinical trial NCT06648824?
This trial is sponsored by Agios Pharmaceuticals, which has 44 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.